A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
← catalyst calendarNCT06602258 · readout in 106 d
Sponsored by Eisai Inc. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
105actual
Sites
26
Countries
Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-30 | actual | When the study began enrolling |
| Primary completion | 2026-12-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-18 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer's Disease
Interventions
- Drug: E2814
- Drug: Lecanemab — also filed as BAN2401, LEQEMBI
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in CSF MTBR-tau-243 at 6 Months
measured Baseline at 6 months
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed